Larry Robbins

Director Larry Robbins sold 3,372,000 shares of CVS for $317,471,136.18 across 7 transactions (May 19-21, 2026), reducing holdings 41.1%.

Larry Robbins, a Director at CVS HEALTH, executed 7 separate sales totaling 3,372,000 shares for $317,471,136.18, reducing his post-transaction holdings to 4,824,799 shares (a net reduction of 41.1% vs pre-transaction holdings of 8,196,799 shares). The blended average sale price was $94.15 across transactions dated May 19–21, 2026, compared to the current price of $93.32, positioning these sales near recent market levels. Robbins' prior 5 sales at CVS were uniformly well-timed at the 90-day mark, with negative 90-day returns ranging from -5.0% to -8.1%, indicating a consistent pattern of selling ahead of subsequent price declines; his cross-ticker track record shows a 100% well-timed rate on 6 prior sells with an average 90-day return of -8.5%. This large, multi-transaction liquidation—while maintaining a substantial residual stake of 4.82M shares—is notable given his demonstrated historical success at timing CVS sales to precede market weakness.

Director Larry Robbins buys 21.4K shares of BFLY at $3.02; continues buying streak (5 prior purchases in 5 days, all untested).

Director Larry Robbins purchased 21,370 shares at $3.02 on 2025-12-11, adding to a rapid sequence of five purchases at the same ticker between 2025-11-20 and 2025-12-05. All five prior trades at BFLY remain unmeasured at the 30- and 90-day horizons, so no pattern of timing success or failure is yet observable at this ticker. Robbins' cross-ticker track record shows a 100% win rate on 10 prior buys with average 90-day returns of +213.8%, but this outsized performance does not transfer predictively to outcomes at BFLY—a company burning $34.0M annually despite +24.5% revenue growth. The continued accumulation in the face of ongoing losses and a stock 33.2% below its 52-week high warrants monitoring as the fundamental picture develops.

Director Robbins purchases 1,558,541 shares across 3 days (Dec 3–5, 2025) for $4,652,772.68 at avg $2.99; holdings +12.2% to 14.31M shares.

Larry Robbins, a director at Butterfly Network, executed 3 separate purchases totaling 1,558,541 shares for $4,652,772.68 between December 3–5, 2025, at a blended average price of $2.99—an increase of 12.2% to his post-transaction holdings of 14,313,685 shares. This substantial open-market accumulation occurred while the stock trades at $3.06, within its 52-week range of $1.33–$4.82 and up 96.2% over the prior 90 days. Robbins' cross-ticker track record is notably strong: 7 prior buys with a 100% 90-day win rate and average 90-day return of +213.8%, along with 6 prior sells all well-timed with a 100% win rate. At BFLY specifically, his 2 measurable prior buys (August 2024) each returned +47.0–47.5% at 30 days and +206.2–207.1% at 90 days. Against this backdrop of material accumulation and a consistent pattern of well-timed transactions across both BFLY and his broader portfolio, the company remains unprofitable (net income of $-34.0M on the latest full-year basis) despite 24.5% annual revenue growth, creating a dynamic tension between insider conviction and balance-sheet reality that warrants investor attention.

Director Larry Robbins purchases 2,800,000 shares at $2.35–$2.58 over 3 days for $6,784,060.00; post-transaction holdings reach 12,755,144 shares (+28.1%)

Larry Robbins, a director at Butterfly Network, executed 3 separate purchases totaling 2,800,000 (2.80M shares) for $6,784,060.00 over November 19–21, 2025, at a blended average price of $2.42, increasing his holdings from 9,955,144 to 12,755,144 shares (+28.1%). His prior trades at BFLY show a consistent pattern: 4 of 4 prior buys were well-timed at the 90-day mark, with gains ranging from +206.2% to +224.1%. The current price of $2.65 is +24.4% above the 30-day average and +74.3% above the 90-day average, suggesting sustained momentum following his acquisition window. However, this purchase occurs in the context of negative fundamentals: the company reported a net income of $-33,971,000.00 ($-34.0M) and remains unprofitable on a full-year basis, despite reporting annual revenue growth of +24.5%. The scale of this transaction—adding 2.8M shares to an already substantial 9.96M-share position—combined with his prior track record at this ticker indicates material conviction, though the profitability gap between revenue growth and operating losses warrants investor attention to the path to profitability.

Director Larry Robbins sold 3,750,000 shares of CVS Health for $253.7M across 6 transactions (May 2–6), reducing stake by 31.4%.

Director Larry Robbins executed 6 separate sales totaling 3,750,000 shares for $253,695,413.04 between May 2–6, 2025, at prices ranging from $66.67 to $69.66 per share. This disposed of 31.4% of his pre-transaction holdings, dropping his stake from 11,946,799 shares to 8,196,799 shares. The blended average selling price of $67.65 sits near the current price of $66.23 and within the 52-week range of $43.78–$70.18, with the stock up 4.0% over 30 days and 18.9% over 90 days. Robbins' cross-ticker track record shows 4 prior buys with an average 90-day return of +213.8% (100% win rate), but that pattern does not address the signal or drivers of this substantial, multi-day sell sequence. The magnitude of shares sold and the sustained nature of the dispositions over three business days warrant investor attention to any concurrent public disclosures regarding strategy, capital allocation, or change in conviction regarding CVS' near-term prospects.

Director Larry Robbins buys 244,774 shares of BFLY at $1.07 on 2024-08-30, expanding stake to 9.96M shares amid -10.2% revenue decline and ongoing losses.

Director Larry Robbins purchased 244,774 shares at $1.07 on 2024-08-30, increasing his holdings from 9.71M to 9.96M shares. This transaction occurs within a sharp acquisition pattern—the director completed three separate purchases over three consecutive trading days (2024-08-28 through 2024-08-30)—suggesting sustained accumulation at a compressed valuation. However, the underlying business context is materially strained: the company reported quarterly revenue of $21.5M against net losses of $-15.7M, with full-year revenue contracting by -10.2% year-over-year and the company unprofitable on an annual basis. The timing relative to current market conditions shows mixed signals: the stock currently trades at $1.51, representing a +49.5% gain over 30 days and +59.3% over 90 days, yet still positioned -20.5% below its 52-week high of $1.90. The prior trades in this same ticker remain outcome-unmeasurable (all within the past three trading days), and the director's cross-ticker track record shows only 3 prior buys total, limiting confidence in pattern analysis.

Director Robbins buys 1,676,869 shares (1.68M) for $1,683,372.82 across 3 transactions at blended $1.00 average, raising stake to 9.71M shares (+20.9%)

Larry Robbins, a Director at Butterfly Network, executed 3 separate purchases totaling 1,676,869 shares for $1,683,372.82 at a blended average price of $1.00 per share on 2024-08-28 and 2024-08-29, increasing his holdings by 20.9% to 9,710,370 shares. The company is facing material headwinds: revenue declined 10.2% year-over-year to $21,487,000 in the latest quarter, and it generated negative net income of $-15,706,000 over its most recent full fiscal year. The stock is currently trading at $1.09, down 42.6% from its 52-week high of $1.90, though it has gained 9.6% over the past 90 days. With minimal cross-ticker buy history and no same-ticker outcomes yet measurable, this large discrete purchase represents a material personal capital commitment during a period of operational underperformance and relative stock weakness.